title: Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy.
abstract: Eflornithine (DFMO) was used to treat 31 AIDS patients with confirmed Pneumocystis carinii pneumonia who had clinically failed treatment with pentamidine, sulphamethoxazole-trimethoprim or both agents as their first-line therapy. Twenty-one of 31 (68%) responded to second-line treatment with 400mg/kg per day of eflornithine. Five patients discontinued treatment because of bone marrow toxicity. Eflornithine appears to be a useful salvage therapy in patients failing first-line treatments.
authors: Westminster Hospital, London, UK.
authors: D
authors: D
authors: Smith
authors: S
authors: S
authors: Davies
authors: M
authors: M
authors: Nelson
authors: M
authors: M
authors: Youle
authors: J
authors: J
authors: Gleeson
authors: B
authors: B
authors: Gazzard
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000518:Eflornithine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006716:Homosexuality; D006801:Humans; D008297:Male; D010419:Pentamidine / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D000518:Eflornithine